SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Curocell Seeks Amendment Approval for CRC01 Phase 3 Trial

Curocell applied to South Korea’s Ministry of Food and Drug Safety on Oct. 30, 2026, to amend the Phase 3 trial of CRC01 (anbalcell) for large B-cell lymphoma.

Related stories